Clinical Trials · NCT00107107

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

Name: Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Pramlintide

Phase: Phase 3
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 190
Start date: Nov 2002
Locations: 25 sites, United States
Primary endpoint: To investigate the long term safety profile of pramlintide treatment in subjects with type 1 diabetes completing protocol 137-150.

View Pramlintide compound reference